<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0"
  xmlns:content="http://purl.org/rss/1.0/modules/content/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:media="http://search.yahoo.com/mrss/"
  xmlns:atom="http://www.w3.org/2005/Atom"
  xmlns:georss="http://www.georss.org/georss">

  <channel>
    <title>
      <![CDATA[  the cedar ledge  ]]>
    </title>
    <link> https://jacobzelko.com </link>
    <description>
      <![CDATA[  Jacob S. Zelko&#39;s personal website  ]]>
    </description>
    <atom:link
      href="https://jacobzelko.com/feed.xml"
      rel="self"
      type="application/rss+xml" />


<item>
  <title>
    <![CDATA[  Could Autism Spectrum Disorders Be A Risk Factor For covid-19?  ]]>
  </title>
  <link> https://jacobzelko.com/07192020034934-asd-risk-factor/index.html </link>
  <guid> https://jacobzelko.com/07192020034934-asd-risk-factor/index.html </guid>
  <description>
    <![CDATA[  Autism Spectrum Disorders as a potential risk factor in COVID-19 outcomes  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Could Autism Spectrum Disorders Be A Risk Factor For covid-19?</h1>
<p><strong>Date:</strong> July 18 2020</p>
<p><strong>Summary:</strong> Autism Spectrum Disorders as a potential risk factor in COVID-19 outcomes</p>
<p><strong>Keywords:</strong> ##bibliography #asd #autism #covid19 ##pandemic #archive</p>
<h1>Bibliography</h1>
<p>M. E. de Sousa Lima, L. C. M. Barros, and G. F. Aragão, &quot;Could Autism Spectrum Disorders be a Risk Factor for COVID-19?,&quot; Med Hypotheses, May 2020, doi: 10.1016/j.mehy.2020.109899.</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li><ol><li>Cytokine Observations in ASD and COVID19</li></ol></li><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<blockquote>
<p><strong>NOTE:</strong> The journal medical hypothesis lacks a standard peer review process, but is often utilized to posit ideas quickly.</p>
</blockquote>
<p><strong>Purpose of paper:</strong> consolidate data to support the hypothesis of ASD being a risk for COVID19 like other risks.</p>
<p>Involves several modifications at the genetic and at the immune level &#40;e.g. increases of inflammatorycytokines and abnormal immune response in several levels&#41;. &#91;1&#93; Some are conditions considered risk-factor of symptomatic COVID-19 and its mortality.</p>
<h3 id="cytokine_observations_in_asd_and_covid19">Cytokine Observations in ASD and COVID19</h3>
<p>Initially there is an endogenous immune response in the presence of COVID19. The response is linked to the destruction level of the virus, the patient’s innateresponse, and it determines its inflammation status and symptomatology. &#91;2&#93;</p>
<p>Secretory increases of ACE-2 was correlated with COVID-19 patients &#91;3&#93;. There seem to exist an ACE-2 superexpression leading to a pro-inflammatory state, related to cardiac and pulmonary damage &#91;3&#93; ACE-2 is a regulator in angiotensin-2transformation into angiotensin-&#40;1-7&#41; metabolite. It has inflammatory effects producing vasodilatation, anti-proliferation and apoptosis. This is common to CVD conditions &#91;4&#93;.</p>
<p>Coronavirus also has the characteristic of being neuroinvasive. &#91;5&#93; This characteristic shows via:- Febrile seizures - Encephalitis - Convulsions - Change in mental status Some neurological symptomsfound in COVID-19 patients are non-specific, such as headache, dizziness and confusion. Neurological symptoms were directly related to patients. &#91;6&#93; Thereby, we can hypothesize that its physiopathology might have a strict relation with the nervous system.</p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Could Autism Spectrum Disorders Be A Risk Factor For covid-19?</em>. <a href="https://jacobzelko.com/07192020034934-asd-risk-factor">https://jacobzelko.com/07192020034934-asd-risk-factor</a>. July 18 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; H. Ormstad, V. Bryn, O. D. Saugstad, O. Skjeldal, and M. Maes, “Role of the immune system in autism spectrum disorders &#40;ASD&#41;,” CNS Neurol. Disord.-Drug Targets Former. Curr. Drug Targets-CNS Neurol. Disord., vol. 17, no. 7, pp. 489–495, 2018.</p>
<p>&#91;2&#93; Y. Shi et al., “COVID-19 infection: The perspectives on immune responses,” 2020.</p>
<p>&#91;3&#93; Y.-Y. Zheng, Y.-T. Ma, J.-Y. Zhang, and X. Xie, “COVID-19 and the cardiovascular system,” Nat. Rev. Cardiol., vol. 17, no. 5, pp. 259–260, 2020.</p>
<p>&#91;4&#93; A. J. Turner, J. A. Hiscox, and N. M. Hooper, “ACE2: From vasopeptidase to SARS virus receptor,” Trends Pharmacol. Sci., vol. 25, no. 6, pp. 291–294, 2004.</p>
<p>&#91;5&#93; A. A. Asadi-Pooya and L. Simani, “Central nervous system manifestations of COVID-19: A systematic review,” J. Neurol. Sci., p. 116832, 2020.</p>
<p>&#91;6&#93; G. Conde, L. D. Q. Pájaro, I. D. Q. Marzola, Y. R. Villegas, and L. R. M. Salazar, “Neurotropism of SARS-CoV 2: Mechanisms and manifestations,” J. Neurol. Sci., 2020.</p>
<h2 id="discussion">Discussion: </h2>
<script>talkyardServerUrl='https://site-vbm8wbc57o.talkyard.net';</script>
<script async defer src="https://c1.ty-cdn.net/-/talkyard-comments.min.js"></script>
<div class="talkyard-comments" data-discussion-id="" style="margin-top: 45px;">
    <noscript>Please enable Javascript to view comments.</noscript>
</div> ]]>
  </content:encoded>
    
  <pubDate>Sat, 18 Jul 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>

<item>
  <title>
    <![CDATA[  Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD  ]]>
  </title>
  <link> https://jacobzelko.com/07102020174816-cytokine-asd-covid19/index.html </link>
  <guid> https://jacobzelko.com/07102020174816-cytokine-asd-covid19/index.html </guid>
  <description>
    <![CDATA[  Loose hypothesis on worsening of cytokine regulation via ASD and COVID19  ]]>
  </description>  
  
  <content:encoded>
    <![CDATA[  
<h1>Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD</h1>
<p><strong>Date:</strong> July 10 2020</p>
<p><strong>Summary:</strong> Loose hypothesis on worsening of cytokine regulation via ASD and COVID19</p>
<p><strong>Keywords:</strong> ##zettel #asd #autism ##hypothesis #health #mentalhealth #cytokine ##pandemic #covid19 #archive</p>
<h1>Bibliography</h1>
<p>Not Available</p>
<h1>Table of Contents</h1>
<div class="franklin-toc"><ol><li>How To Cite</li><li>References</li><li>Discussion: </li></ol></div>
<blockquote>
<p><strong>Note:</strong> Be careful about conflating correlation with causation.</p>
</blockquote>
<p>I have been closely examining the Hypothalamus Pituitary &#40;HPA&#41; axis and have seen how cytokines directly interact with it. &#91;1&#93; Therefore, since ASD has been correlated with cytokine dysregulation &#91;2&#93;, it can be reasonable to suspect that as coronavirae can also impact cytokine regulation &#91;3&#93;, ASD is a risk factor for COVID19 causing direct problems with the HPA axis leading to multiple downstream issues.</p>
<p>ASD has been correlated with abnormal immune function. This includes:</p>
<ol>
<li><p>Cytokine dysregulation</p>
</li>
<li><p>Inflammation</p>
</li>
<li><p>Presence of autoantibodies</p>
</li>
</ol>
<p>Studies show the presence of anti-brain immunoglobulins in ASD patients. &#91;4&#93; ASD status could also be directly correlated with patients’ cytokine and chemokine levels which cause organ inflammation &#91;2&#93;</p>
<p>There is a second phase resulting in a cytokine storm which particularly affects respiratory epithelium &#91;5&#93;. The storm activates cytokines IL-1-beta, IL-6 and TNFalfa. These activations aggravate respiratory symptoms. These cytokines cause damage to pulmonary microvasculature. It simultaneously affects apoptosis and chemotaxis resulting in decreases of epithelial barriers and alveolar edema <em>Back up references about cytokines</em></p>
<h2 id="how_to_cite">How To Cite</h2>
<p>Zelko, Jacob. <em>Hypothesis on Cytokine Dysregulation Worsened by COVID19 for People with ASD</em>. <a href="https://jacobzelko.com/07102020174816-cytokine-asd-covid19">https://jacobzelko.com/07102020174816-cytokine-asd-covid19</a>. July 10 2020.</p>
<h2 id="references">References</h2>
<p>&#91;1&#93; M. Marmot and R. Wilkinson, Social Determinants of Health, 2nd ed. Oxford University Press, 2006.</p>
<p>&#91;2&#93; A. M. Depino, “Peripheral and central inflammation in autism spectrum disorders,” Mol. Cell. Neurosci., vol. 53, pp. 69–76, 2013.</p>
<p>&#91;3&#93; S. N. J. Korsman, G. U. van Zyl, L. Nutt, M. I. Andersson, and W. Preiser, “Human coronaviruses,” in Virology, Elsevier, 2012, pp. 94–95. doi: 10.1016/B978-0-443-07367-0.00040-9.</p>
<p>&#91;4&#93; A. Meltzer and J. Van de Water, “The role of the immune system in autism spectrum disorder,” Neuropsychopharmacology, vol. 42, no. 1, pp. 284–298, 2017.</p>
<p>&#91;5&#93; Q. Ye, B. Wang, and J. Mao, “Cytokine storm in COVID-19 and treatment,” J. Infect., 2020.</p>
<h2 id="discussion">Discussion: </h2>
<script>talkyardServerUrl='https://site-vbm8wbc57o.talkyard.net';</script>
<script async defer src="https://c1.ty-cdn.net/-/talkyard-comments.min.js"></script>
<div class="talkyard-comments" data-discussion-id="" style="margin-top: 45px;">
    <noscript>Please enable Javascript to view comments.</noscript>
</div> ]]>
  </content:encoded>
    
  <pubDate>Fri, 10 Jul 2020 00:00:00 +0000</pubDate>  
  
  
  <atom:author>
    <atom:name>Jacob Zelko</atom:name>
  </atom:author>
        
</item>
</channel></rss>